Do analysts rate NBRV or MDWD?

MediWound has a consensus price target of $34.00, suggesting a potential upside of 139.10%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Nabriva Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 MediWound 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts rate EQ or NBRV?

Equillium currently has a consensus price target of $7.57, suggesting a potential upside of 169.45%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than Nabriva Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Equillium 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate TLSA or NBRV?

Given Nabriva Therapeutics' higher probable upside, analysts clearly believe Nabriva Therapeutics is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, TLSA or NBRV?

Tiziana Life Sciences has higher earnings, but lower revenue than Nabriva Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A Nabriva Therapeutics $35.59M 0.00 -$57.19M -$19.20 N/A

Nabriva Therapeutics (NBRV) Competitors

Compare

NBRV vs. MDWD, EQ, TLSA, TNYA, and ABOS

Should you buy Nabriva Therapeutics stock or one of its competitors? MarketBeat compares Nabriva Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nabriva Therapeutics include MediWound (MDWD), Equillium (EQ), Tiziana Life Sciences (TLSA), Tenaya Therapeutics (TNYA), and Acumen Pharmaceuticals (ABOS). These companies are all part of the "pharmaceutical products" industry.

How does Nabriva Therapeutics compare to MediWound?

Nabriva Therapeutics (NASDAQ:NBRV) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, dividends, risk and analyst recommendations.

MediWound has a consensus price target of $34.00, suggesting a potential upside of 139.10%. Given MediWound's stronger consensus rating and higher probable upside, analysts plainly believe MediWound is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Nabriva Therapeutics has a net margin of -148.11% compared to MediWound's net margin of -180.30%. MediWound's return on equity of -67.22% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%
MediWound	-180.30%	-67.22%	-31.87%

0.3% of Nabriva Therapeutics shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 1.6% of Nabriva Therapeutics shares are held by insiders. Comparatively, 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, MediWound had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 1 mentions for MediWound and 0 mentions for Nabriva Therapeutics. MediWound's average media sentiment score of 1.89 beat Nabriva Therapeutics' score of 0.00 indicating that MediWound is being referred to more favorably in the news media.

Company	Overall Sentiment
Nabriva Therapeutics	Neutral
MediWound	Very Positive

Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, MediWound has a beta of 0.16, indicating that its stock price is 84% less volatile than the broader market.

MediWound has lower revenue, but higher earnings than Nabriva Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A
MediWound	$16.96M	10.77	-$23.88M	-$2.26	N/A

Summary

MediWound beats Nabriva Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Nabriva Therapeutics compare to Equillium?

Equillium (NASDAQ:EQ) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Equillium has higher revenue and earnings than Nabriva Therapeutics. Equillium is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Equillium	$41.10M	4.32	-$22.40M	-$0.32	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Equillium has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market.

Equillium currently has a consensus price target of $7.57, suggesting a potential upside of 169.45%. Given Equillium's stronger consensus rating and higher probable upside, analysts clearly believe Equillium is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Equillium	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Equillium had 3 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 3 mentions for Equillium and 0 mentions for Nabriva Therapeutics. Equillium's average media sentiment score of 0.93 beat Nabriva Therapeutics' score of 0.00 indicating that Equillium is being referred to more favorably in the media.

Company	Overall Sentiment
Equillium	Positive
Nabriva Therapeutics	Neutral

27.1% of Equillium shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 17.8% of Equillium shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Equillium has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Equillium's return on equity of -61.43% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Equillium	N/A	-61.43%	-53.72%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Summary

Equillium beats Nabriva Therapeutics on 15 of the 16 factors compared between the two stocks.

How does Nabriva Therapeutics compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, valuation, media sentiment, analyst recommendations, profitability, earnings, dividends and institutional ownership.

Tiziana Life Sciences has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Tiziana Life Sciences' return on equity of 0.00% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Given Nabriva Therapeutics' higher probable upside, analysts clearly believe Nabriva Therapeutics is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Tiziana Life Sciences had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 1 mentions for Tiziana Life Sciences and 0 mentions for Nabriva Therapeutics. Tiziana Life Sciences' average media sentiment score of 1.87 beat Nabriva Therapeutics' score of 0.00 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Very Positive
Nabriva Therapeutics	Neutral

Tiziana Life Sciences has higher earnings, but lower revenue than Nabriva Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Tiziana Life Sciences has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

0.3% of Nabriva Therapeutics shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Tiziana Life Sciences beats Nabriva Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Nabriva Therapeutics compare to Tenaya Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Tenaya Therapeutics has a beta of 2.82, indicating that its stock price is 182% more volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market.

In the previous week, Tenaya Therapeutics had 1 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 1 mentions for Tenaya Therapeutics and 0 mentions for Nabriva Therapeutics. Tenaya Therapeutics' average media sentiment score of 1.87 beat Nabriva Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Tenaya Therapeutics	Very Positive
Nabriva Therapeutics	Neutral

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tenaya Therapeutics currently has a consensus price target of $4.00, indicating a potential upside of 461.96%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Tenaya Therapeutics is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Nabriva Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Tenaya Therapeutics has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Tenaya Therapeutics' return on equity of -80.56% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Summary

Tenaya Therapeutics beats Nabriva Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Nabriva Therapeutics compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Acumen Pharmaceuticals has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its share price is 53% more volatile than the broader market.

In the previous week, Acumen Pharmaceuticals had 4 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 0 mentions for Nabriva Therapeutics. Acumen Pharmaceuticals' average media sentiment score of 0.59 beat Nabriva Therapeutics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Acumen Pharmaceuticals	Positive
Nabriva Therapeutics	Neutral

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Acumen Pharmaceuticals has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Acumen Pharmaceuticals' return on equity of -123.07% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

Nabriva Therapeutics has higher revenue and earnings than Acumen Pharmaceuticals. Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Acumen Pharmaceuticals presently has a consensus target price of $6.67, indicating a potential upside of 181.29%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Acumen Pharmaceuticals is more favorable than Nabriva Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Acumen Pharmaceuticals beats Nabriva Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Nabriva Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NBRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NBRV vs. The Competition

Export

Metric	Nabriva Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$45.46M	$979.54M	$6.52B	$12.05B
Dividend Yield	N/A	4.84%	2.67%	5.66%
P/E Ratio	0.00	1.45	24.00	24.42
Price / Sales	N/A	120.49	514.36	111.24
Price / Cash	N/A	20.06	27.48	37.92
Price / Book	N/A	7.85	10.54	6.82
Net Income	-$57.19M	-$4.88M	$3.57B	$337.56M

Nabriva Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70	Gap Up
MDWD MediWound	3.4685 of 5 stars	$13.74 -0.1%	$34.00 +147.4%	-30.4%	$176.85M	$16.96M	N/A	80
EQ Equillium	2.9703 of 5 stars	$3.11 +11.5%	$7.57 +143.5%	+709.8%	$176.40M	$41.10M	N/A	40	Analyst Upgrade High Trading Volume
TLSA Tiziana Life Sciences	1.0164 of 5 stars	$1.18 -13.2%	N/A	-29.0%	$173.07M	N/A	N/A	8	Positive News Upcoming Earnings Gap Up High Trading Volume
TNYA Tenaya Therapeutics	2.5488 of 5 stars	$0.79 -0.5%	$4.00 +409.0%	+20.3%	$171.43M	N/A	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NBRV) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nabriva Therapeutics (NBRV) Competitors

NBRV vs. MDWD, EQ, TLSA, TNYA, and ABOS

How does Nabriva Therapeutics compare to MediWound?

Summary

How does Nabriva Therapeutics compare to Equillium?

Summary

How does Nabriva Therapeutics compare to Tiziana Life Sciences?

Summary

How does Nabriva Therapeutics compare to Tenaya Therapeutics?

Summary

How does Nabriva Therapeutics compare to Acumen Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBRV vs. The Competition

Nabriva Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nabriva Therapeutics (NBRV) Competitors

NBRV vs. MDWD, EQ, TLSA, TNYA, and ABOS

How does Nabriva Therapeutics compare to MediWound?

Do analysts rate NBRV or MDWD?

Is NBRV or MDWD more profitable?

Do institutionals & insiders have more ownership in NBRV or MDWD?

Does the media favor NBRV or MDWD?

Which has more volatility & risk, NBRV or MDWD?

Which has better earnings and valuation, NBRV or MDWD?

Summary

How does Nabriva Therapeutics compare to Equillium?

Which has stronger valuation & earnings, EQ or NBRV?

Which has more volatility and risk, EQ or NBRV?

Do analysts rate EQ or NBRV?

Does the media prefer EQ or NBRV?

Do institutionals and insiders hold more shares of EQ or NBRV?

Is EQ or NBRV more profitable?

Summary

How does Nabriva Therapeutics compare to Tiziana Life Sciences?

Is TLSA or NBRV more profitable?

Do analysts rate TLSA or NBRV?

Does the media refer more to TLSA or NBRV?

Which has higher valuation & earnings, TLSA or NBRV?

Which has more volatility and risk, TLSA or NBRV?

Do insiders and institutionals believe in TLSA or NBRV?

Summary

How does Nabriva Therapeutics compare to Tenaya Therapeutics?

Which has more risk and volatility, TNYA or NBRV?

Does the media prefer TNYA or NBRV?

Do institutionals & insiders believe in TNYA or NBRV?

Do analysts prefer TNYA or NBRV?

Which has stronger valuation & earnings, TNYA or NBRV?

Is TNYA or NBRV more profitable?

Summary

How does Nabriva Therapeutics compare to Acumen Pharmaceuticals?

Which has more risk & volatility, ABOS or NBRV?

Does the media prefer ABOS or NBRV?

Do institutionals and insiders believe in ABOS or NBRV?

Is ABOS or NBRV more profitable?

Which has better earnings and valuation, ABOS or NBRV?

Do analysts prefer ABOS or NBRV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NBRV vs. The Competition

Nabriva Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools